관절통 주사 시장 예측(-2030년) : 관절 유형, 주사 유형, 유통 채널, 최종 사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Joint Pain Injections Market is accounted for $5.2 billion in 2023 and is expected to reach $10.7 billion by 2030 growing at a CAGR of 10.6% during the forecast period. Direct injections into the joints are used to treat joint pain in order to reduce swelling and inflammation. In the elderly population, joint discomfort is typically brought on by pre-existing conditions. The widespread ailment known as arthritis mostly affects the hip, knee, elbow, shoulder, and facet joints of the spine. It causes inflammation in the joints and makes them uncomfortable.

According to the Arthritis Research UK report, "The State of Musculoskeletal Health 2018", it is estimated that 17.8 million people suffer with a musculoskeletal condition in the UK which is around 28.9% of the total population of the country.

Market Dynamics:

Driver:

Increased occurrence of arthritis

The most frequent cause of adult disability worldwide is arthritis. Corticosteroids and hyaluronic acid injections, for example, can significantly reduce pain by lubricating the joints and decreasing inflammation, which relieves stiffness and discomfort. By carefully administering medicine to the region of pain or inflammation, injections target the afflicted joint, increasing efficacy and minimizing systemic adverse effects. The market is expanding as a result of these causes.

Restraint:

Side effects and allergies

Joint pain injection side effects and allergies that patients experienced have turned out to be a significant barrier to the market's expansion. Some patients who had joint pain injections had damage to their cartilage and nerves, which has had an impact on the manufacturing and marketing of these medical devices. Furthermore, the largest obstacle to the industry's expansion has been shown to be skin discoloration and infections that result from patients using joint pain inoculations.

Opportunity:

Growing prevalence of joint-related disorders

One driver of the market is the growing prevalence of joint-related disorders. The increasing incidence of conditions such as osteoarthritis and rheumatoid arthritis has created a substantial demand for effective pain management solutions, including joint pain injections. The rising aging population, sedentary lifestyles, and sports-related injuries further contribute to the market growth.

Threat:

Lack of knowledge

The average population has never heard about joint pain injections. Platelet-rich plasma, corticosteroids, and hyaluronic acid injections are used to relieve joint discomfort. To utilize these injections, one must possess a great deal of expertise and training. Physicians and other medical professionals frequently inject people for joint discomfort. The tools and training needed for professionals to do this are supplied. The lack of government measures to encourage joint pain injections, however, limits the market's growth.

COVID-19 Impact:

The COVID-19 pandemic has turned out to be an unparalleled worldwide public health disaster that has impacted practically every business, and its repercussions are anticipated to have an impact on every industry's growth over the projection period. Globally, there have been several shifts in supply chain rerouting, purchasing patterns, customer demand and behavior, and major government efforts. The epidemic has altered people's lifestyles, drug usage patterns, and other health-related habits.

The hyaluronic acid injections segment is expected to be the largest during the forecast period

The hyaluronic acid injections segment is expected to be the largest during the forecast period. Patients who have already tried ineffective treatments like acetaminophen and other opioids are treated with hyaluronic acid injections for knee discomfort associated with osteoarthritis. Injections of hyaluronic acid have grown in favor as a non-surgical treatment option, especially considering that physicians are generally reluctant to administer intraarticular corticosteroid injections on a regular basis.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Hospital pharmacies frequently employ medical professionals with specific training in injectable administration in addition to competent pharmacists, assuring correct technique and lowering the chance of problems. Patients have access to a wider range of pain management options, including different types of injections or combination therapies tailored to their specific needs.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the high prevalence of musculoskeletal disorders, growing geriatric population. This is ascribed to a number of factors, including the large concentration of market participants in the area, the robust presence of industry companies in the area, improved healthcare infrastructure, and public and industry stakeholder knowledge of available technology. The market in this area is expanding due in part to a high rate of adoption of cutting-edge technology.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The rising incidence of osteoarthritis and the entry of viscosupplement products by regional competitors are propelling the growth of the respective markets in each country. Furthermore, ideal circumstances for the patient population's acceptance of these therapies are created by the growing knowledge of cutting-edge joint pain treatments in the area.

Key players in the market:

Some of the key players in Joint Pain Injections market include Anika Therapeutics, Inc., Sanofi aventis LLC, Ferring B.V., Zimmer Biomet, Bioventus LLC, Allergen Plc., Pfizer Inc., Chugai Pharmaceutical Co. Ltd, SEIKAGAKU Corporation, Ferring B.V., Pacira Biosciences, OrthogenRx, Pfizer, Lifecore Biomedical, Wright Medical Group, AbbVie and Stryker.

Key Developments:

In January 2023, AbbVie received the United States Food and Drug Administration (FDA) approval for SKYRIZI (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), which can be administered with a single injection four times a year.

In March 2022, Sanofi collaborated with IGM Biosciences Inc. to develop, manufacture, and introduce potential therapeutics in the fields of immunology and inflammation.

Joint Types Covered:

• Shoulder and Elbow
• Facet Joints of the Spine
• Knee and Ankle
• Hip Joint
• Other Joint Types

Injection Types Covered:

• Interleukin Inhibitors
• Hyaluronic Acid Injections
• Steroid Joint Injections
• Platelet-rich Plasma (PRP) Injections
• Placental Tissue Matrix (PTM) Injections
• Other Injection Types

Distribution Channels Covered:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

End Users Covered:

• Hospitals
• Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introducton
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Joint Pain Injections Market, By Joint Type

• 5.1 Introduction
• 5.2 Shoulder and Elbow
• 5.3 Facet Joints of the Spine
• 5.4 Knee and Ankle
• 5.5 Hip Joint
• 5.6 Other Joint Types

6 Global Joint Pain Injections Market, By Injection Type

• 6.1 Introduction
• 6.2 Interleukin Inhibitors
• 6.3 Hyaluronic Acid Injections
• 6.4 Steroid Joint Injections
• 6.5 Platelet-rich Plasma (PRP) Injections
• 6.6 Placental Tissue Matrix (PTM) Injections
• 6.7 Other Injection Types

7 Global Joint Pain Injections Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Retail Pharmacies
• 7.3 Hospital Pharmacies
• 7.4 Online Pharmacies

8 Global Joint Pain Injections Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Other End Users

9 Global Joint Pain Injections Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Anika Therapeutics, Inc.
• 11.2 Sanofi aventis LLC
• 11.3 Ferring B.V.
• 11.4 Zimmer Biomet
• 11.5 Bioventus LLC
• 11.6 Allergen Plc.
• 11.7 Pfizer Inc.
• 11.8 Chugai Pharmaceutical Co. Ltd
• 11.9 SEIKAGAKU Corporation
• 11.10 Ferring B.V.
• 11.11 Pacira Biosciences
• 11.12 OrthogenRx
• 11.13 Pfizer
• 11.14 Lifecore Biomedical
• 11.15 Wright Medical Group
• 11.16 AbbVie
• 11.17 Stryker